Washington, D.C., August 24, 2026
Vanda Pharmaceuticals Inc. announced that the European Commission has granted Orphan Designation to imsidolimab for the treatment of generalized pustular psoriasis (GPP), following a positive opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products. The designation marks an important regulatory milestone for Vanda’s investigational therapy in Europe and expands the drug’s orphan regulatory recognition across the European Union, United States and Japan. Imsidolimab is being developed for GPP, a rare, severe and potentially life-threatening inflammatory skin disorder associated with dysregulation of the interleukin-36 (IL-36) signaling pathway. The European designation is intended for medicines addressing rare conditions that affect fewer than 5 in 10,000 people in the EU and can provide development-related regulatory benefits, including protocol assistance, reduced regulatory fees and potential market exclusivity following approval.
Imsidolimab Targets IL-36 Signaling in GPP
Imsidolimab is a fully humanized IgG4 monoclonal antibody designed to inhibit IL-36 receptor signaling, directly targeting an important biological pathway implicated in generalized pustular psoriasis. Unlike plaque psoriasis, GPP is characterized by widespread pustular eruptions accompanied by systemic inflammation and potentially serious complications. The disease can become life-threatening and represents a significant unmet medical need because patients may experience severe and recurrent inflammatory episodes. Vanda is developing imsidolimab specifically for this rare indication, with the therapeutic strategy focused on interrupting IL-36 receptor-mediated inflammatory signaling. The company said the European Commission’s designation represents the first time an EU orphan designation has been granted for a drug intended to treat GPP, adding a notable regulatory distinction to the program as Vanda advances development across major international markets.
European Designation Adds Regulatory Benefits
The EU Orphan Designation provides several potential advantages during drug development, particularly for therapies targeting rare diseases such as GPP. Following a positive COMP opinion, the European Commission grants the designation when regulatory criteria are met, including the rarity and serious nature of the condition. For Vanda, the designation may provide access to EMA protocol assistance and reduced regulatory fees, while orphan status can also support market exclusivity provisions if imsidolimab ultimately receives marketing authorization. The designation does not itself mean that imsidolimab is approved for GPP, and additional clinical and regulatory requirements must still be satisfied before commercialization. Vanda stated that regulatory and patent exclusivity for imsidolimab is expected to extend into the late 2030s, while the company retains an exclusive global license for the therapy’s development and commercialization.
Advertisement
FDA Review Sets Next Major Milestone
The European regulatory milestone comes as imsidolimab continues through the U.S. regulatory process, with Vanda’s Biologics License Application for GPP currently under review by the U.S. Food and Drug Administration. The FDA has established a target action date of December 12, 2026, making the upcoming regulatory decision a major catalyst for the program. Imsidolimab has previously received Orphan Drug Designation from both the FDA and Japan’s Ministry of Health, Labour and Welfare, giving the program orphan recognition across three major regulatory regions. Vanda said it remains focused on advancing imsidolimab for patients with GPP who need additional treatment options. However, the European designation and pending FDA review should not be interpreted as evidence of approval or confirmed clinical benefit; the therapy remains investigational in this indication until applicable regulatory authorities complete their reviews.
Source:Vanda Pharmaceuticals press relese
